Crinetics Pharmaceuticals, Inc. announced significant findings from its recent research on the investigational candidate paltusotine for the treatment of acromegaly. The studies, presented at the American Association of Clinical Endocrinology Annual Meeting 2025, highlighted paltusotine's rapid and durable effects in managing IGF-1 levels in surgically naïve patients, indicating it was well tolerated. Additionally, the research underscored the considerable symptom burden that patients on long-acting injectable somatostatin analogs may experience. These developments suggest that, if approved, paltusotine, a novel once-daily oral medication, could represent a meaningful advancement in the standard of care for individuals with acromegaly. Regulatory reviews in the U.S. and EU are progressing, with a PDUFA action date set for September 25 in the U.S.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.